1 / 20

Roche Pharmaceuticals Site Visit 2007

Roche Pharmaceuticals Site Visit 2007. February 9, 2007 Brian Johnson Dimitrios Kandylas. Roche in Brief. Hoffman-LaRoche Inc. Nutley, NJ www.rocheusa.com President & CEO: George B. Abercrombie Core businesses in pharmaceuticals and diagnostics #1 pharma in the world in oncology sales

minerva-stephens
Download Presentation

Roche Pharmaceuticals Site Visit 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Roche PharmaceuticalsSite Visit 2007 February 9, 2007Brian JohnsonDimitrios Kandylas

  2. Roche in Brief • Hoffman-LaRoche Inc. Nutley, NJ • www.rocheusa.com • President & CEO: George B. Abercrombie • Core businesses in pharmaceuticals and diagnostics • #1 pharma in the world in oncology sales • 1950’s discovery of benzodiazepine class of compounds – resulted in Valium

  3. Recent Revival • Struggled at turn of century due to drug failures and a price-fixing scandal • Now attracting market attention mostly because of strong pipeline • 2005 pharma sales up 25% • 2005 diagnostics sales up 4%

  4. Key Therapeutic Areas • Central Nervous System • Dermatology • Inflammation/ Bone Disorders – Rheumatoid Arthritis • Metabolic Diseases – Obesity, Diabetes • Oncology - NJ • Respiratory Diseases • Transplantation • Vascular Diseases • Virology – HIV/ AIDS and Hep C

  5. Tamiflu Avastin Rituxan Herceptin Tarceva CellCept Xeloda Pegasys Xolair Epogin 62% of pharma sales Out of top 20 products, these 10 are most responsible for growth and profits Oncology division very strong Many governments have been increasing their stocks of Tamiflu Top 10 Growth Drivers

  6. Key Products – The #1’s • Xenical - #1 prescribed weight loss drug in the U.S. The first in the world to prevent intestines from absorbing ~1/3 of fat. • Xeloda - #1 oral chemotherapeutic agent for late stage metastatic breast cancer and colorectal cancer. World’s first oral chemotherapy treatment. Tumor selective.

  7. #1’s Continued • Tamiflu - #1 influenza prescription medicine in the U.S. The worlds first oral flu pill effective against all common strains of the flu virus.

  8. Key Products - Continued • Pegasys – Enhances the properties of interferon, making it more effective against Hep-C. Less-frequent injections necessary. • CellCept – Prevention of rejection for patients receiving kidney, heart and liver organ transplants. • Boniva – The first monthly oral/ quarterly injection for the treatment and prevention of osteoporosis in postmenopausal women.

  9. Key Products - Continued • Tarceva – oncology. Blocks cancer cell signaling. • Fuzeon – HIV fusion inhibitor. Prevents HIV from infecting T cells.

  10. Key Late-Phase Products • Lencentis – launched 6/06. Indication for diabetic macular edema • Rituxan/ MabThera – non-Hodgkins lymphoma; marks infected wbc’s for immune response • Actemra – Phase 3; rheumatoid arthritis • Mircera – seeking indication for treatment of anemia associated with chronic kidney disease

  11. The Roche Pipeline • Roche has said that is currently has 12 drugs either on the market or in late-stage development, each capable of generating $800 million • 58 NMEs and 35 additional indications – 6/05 • Plans to submit 25 regulatory filings over next 5 years • Rheumatoid arthritis, diabetes, asthma, depression

  12. Genomics • Studying information encoded in the DNA • Roche seeking genetic abnormalities underlying diseases or predispositions to prevent or diagnose them earlier • Diabetes, asthma, rheumatism, cancer

  13. Genentech • Californian biotech • BioOncology: Avastin, Herceptin, Rituxan, Tarceva • Immunology • Tissue Growth and Repair • $1.6 billion in R&D

  14. Chugai Pharmaceutical • Top 10 Japanese pharmaceutical • Genomic antibody drug discovery • Collaborated with Roche/ Genentech on Avastin, Tarceva, Xeloda, Herceptin

  15. Roche Diagnostics • Accu-Check – diabetes monitoring for home use • Hospital and laboratory equipment – clinical diagnostics, molecular diagnostics, blood screening

  16. Pharmaceutical Marketing • Several Different “Consumers” ● Doctors – traditional focus ● Patients – drive primary demand ● MCO’s – moving up the hierarchy?

  17. Pharmaceutical Marketing • Physician Targeting – ● Large Sales Force ● Journal Ad’s ● E-Detailing ● Peer Influence – key opinion leaders ● Deciles

  18. Pharmaceutical Marketing • Patient Targeting ● DTC – $700 million in 1997 to over $4 billion ● Creative new outlets – Tamiflu/Happy Feet ● Patient support groups ● Awareness Ad’s

  19. Pharmaceutical Marketing • MCO ● The vital cog in the process ● Increasing focus on payer ● Account Management ● Favored nation status

  20. Pharmaceutical Marketing • DDMAC (Division of Drug Marketing, Advertising, and Communication)– review of labeling and advertising • Prescription Drug Marketing Act of 1987 – regulates marketing of pharmaceuticals

More Related